Anthem Bioscienc

Is Anthem Bioscienc overvalued or undervalued?

As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.<BR><BR>In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.

How has been the historical performance of Anthem Bioscienc?

Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.

Answer:<BR>The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,356.72 Cr. The cash flow from operating activities saw a notable rise to 418.00 Cr from 140.00 Cr, contributing to a net cash inflow of 132.00 Cr, reversing the outflow of 158.00 Cr in the previous year. Overall, Anthem Bioscienc demonstrated robust growth in sales, profits, and cash flow, indicating a strong financial performance.

When is the next results date for Anthem Biosciences Ltd?

The next results date for Anthem Biosciences Ltd is 19 May 2026.

The next results date for Anthem Biosciences Ltd is scheduled for 19 May 2026.

Are Anthem Biosciences Ltd latest results good or bad?

Anthem Biosciences Ltd's latest Q4 FY26 results are strong, with a net profit increase of 104.44% quarter-over-quarter and revenue up 44.38%. However, the stock's high valuation has led analysts to issue a cautious "SELL" rating, resulting in a mixed overall assessment.

Anthem Biosciences Ltd's latest results for Q4 FY26 are quite strong, indicating a significant turnaround from the previous quarter. The company reported a net profit of ₹189.76 crores, which is a remarkable increase of 104.44% quarter-over-quarter and 129.68% year-over-year. Revenue also saw a substantial rise, reaching ₹610.94 crores, reflecting a 44.38% increase from the previous quarter and a 26.44% increase compared to the same quarter last year.<BR><BR>Additionally, the operating margin has improved to 43.74%, marking the highest level in eight quarters, which demonstrates enhanced operational efficiency. The return on equity stands at a solid 24.12%, showcasing strong capital efficiency.<BR><BR>However, despite these impressive financial metrics, the stock is trading at a high valuation of 72 times trailing earnings and 15.30 times book value, which is significantly above industry averages. This elevated valuation has led analysts to adopt a cautious stance, with a "SELL" rating on the stock.<BR><BR>In summary, while the financial performance is strong and shows positive growth trends, the high valuation raises concerns about the sustainability of such multiples, making the overall assessment mixed.

Has Anthem Biosciences Ltd declared dividend?

Yes, Anthem Biosciences Ltd has declared a 100% dividend, with an ex-date of June 25, 2026. However, the company has shown no price or dividend returns over the longer periods, indicating a need for performance improvement.

Anthem Biosciences Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>Percentage announced: 100%<BR>Ex-date: 25 Jun 26<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, Anthem Biosciences Ltd achieved a price return of 13.0%, a dividend return of 0.29%, resulting in a total return of 13.29%.<BR><BR>Over the past 6 months, the company recorded a price return of 21.11%, a dividend return of 0.32%, leading to a total return of 21.43%.<BR><BR>For the 1-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 2-year period, the company saw no price return or dividend return, culminating in a total return of 0.0%.<BR><BR>Over the last 3 years, there were no price or dividend returns, resulting in a total return of 0.0%.<BR><BR>In the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Finally, in the 5-year period, there were no price or dividend returns, resulting in a total return of 0.0%.<BR><BR>Overall, while Anthem Biosciences Ltd has declared a significant dividend, the total returns over the longer periods indicate a lack of growth in price and dividends, suggesting a need for improvement in performance.

Should I buy, sell or hold Anthem Biosciences Ltd?

Which are the latest news on Anthem Bioscienc?

Why is Anthem Biosciences Ltd falling/rising?

As of 24-May, Anthem Biosciences Ltd's stock price is rising due to a trend reversal after previous declines, increased investor participation, strong financial performance, and growing institutional interest. These factors indicate a positive shift in market sentiment and confidence in the company's future.

As of 24-May, Anthem Biosciences Ltd's stock price is rising, currently at 776.55, reflecting an increase of 7.4 (0.96%). This upward movement can be attributed to several factors. Firstly, the stock has shown a trend reversal, gaining after three consecutive days of decline, indicating a potential shift in market sentiment. Additionally, the stock has outperformed its sector by 1.64% today, which suggests strong relative performance compared to its peers.<BR><BR>Investor participation has also increased, with delivery volume rising by 45.1% against the five-day average, signaling growing interest among investors. Furthermore, the company has demonstrated strong long-term fundamentals, highlighted by an average Return on Equity (ROE) of 19.93% and significant growth in operating profit at an annual rate of 44.32%. The recent positive financial results, including the highest net sales and operating profit margins, further bolster investor confidence.<BR><BR>Moreover, institutional investors have increased their stake in the company by 3.87% over the previous quarter, now holding 12.83% of the company. This increase in institutional ownership often reflects a more favorable outlook on the company's future performance, as these investors typically conduct thorough analyses of the companies they invest in.<BR><BR>In summary, the combination of a trend reversal, increased investor participation, strong financial performance, and growing institutional interest are key factors contributing to the rise in Anthem Biosciences Ltd's stock price.